Versant Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Versant Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$44.3K	Buy	2,558 +125	+5%	+$1.71K	﹤0.01%	1439
2026 Q1	$30.2K	Hold	2,433	–	–	﹤0.01%	1566
2025 Q4	$30.7K	Hold	2,433	–	–	﹤0.01%	1373
2025 Q3	$24.4K	Buy	2,433 +490	+25%	+$4.4K	﹤0.01%	1476
2025 Q2	$15.7K	Buy	+1,943	New	+$14.6K	﹤0.01%	1657
2022 Q2	–	Sell	-87	Closed	–	–	1432
2022 Q1	$0	Hold	87	–	–	﹤0.01%	1446
2021 Q4	$0	Hold	87	–	–	﹤0.01%	1425
2021 Q3	$0	Hold	87	–	–	﹤0.01%	1437
2021 Q2	$0	Hold	87	–	–	﹤0.01%	1431
2021 Q1	$1K	Hold	87	–	–	﹤0.01%	1311
2020 Q4	$0	Hold	87	–	–	﹤0.01%	1329
2020 Q3	$0	Hold	87	–	–	﹤0.01%	1289
2020 Q2	$0	Hold	87	–	–	﹤0.01%	1276
2020 Q1	$0	Hold	87	–	–	﹤0.01%	1292
2019 Q4	$0	Buy	+87	New	+$302	﹤0.01%	1343
2019 Q2	–	Sell	-19	Closed	–	–	1386
2019 Q1	$0	Sell	19 -1,115	-98%	-$14.7K	﹤0.01%	1544
2018 Q4	$15K	Hold	1,134	–	–	0.01%	643
2018 Q3	$25K	Buy	+1,134	New	+$23.9K	0.01%	524

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Versant Capital Management's AMRX Position: Q2 2026 in Review

Versant Capital Management increased its Amneal Pharmaceuticals (AMRX) stake by 5.1% in Q2 2026, buying an estimated $1.71K and bringing the position to 2,558 shares worth $44.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1439.

Versant Capital Management first reported a position in AMRX in Q3 2018 and has held it in 18 quarters since. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Versant Capital Management held 2,558 shares of Amneal Pharmaceuticals worth $44.3K as of Q2 2026.
Versant Capital Management bought 125 Amneal Pharmaceuticals shares in Q2 2026, an estimated $1.71K.
Amneal Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1439 holding.
Versant Capital Management first reported a position in Amneal Pharmaceuticals in Q3 2018 and has held it in 18 quarters since.
310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.